Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) - Pipeline Review, H2 2016

  • ID: 3984521
  • Report
  • 64 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Alkermes Plc
  • Cyxone AB
  • Transgene SA
  • ZIOPHARM Oncology, Inc.
  • MORE
Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) - Pipeline Review, H2 2016

Summary

‘Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) - Pipeline Review, H2 2016’, provides in depth analysis on Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) targeted pipeline therapeutics.

The report provides comprehensive information on the Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) targeted therapeutics development and features dormant and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:
- Certain sections in the report may be removed or altered based on the availability and relevance of data.
- Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2)
- The report reviews Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Alkermes Plc
  • Cyxone AB
  • Transgene SA
  • ZIOPHARM Oncology, Inc.
  • MORE
List of Tables

List of Figures

Introduction

Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) Overview

Therapeutics Development

Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) - Products under Development by Stage of Development

Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) - Products under Development by Therapy Area

Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) - Products under Development by Indication

Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) - Pipeline Products Glance

Late Stage Products

Early Stage Products

Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) - Products under Development by Companies

Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) - Products under Development by Universities/Institutes

Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) - Companies Involved in Therapeutics Development

Alkermes Plc

Biomar Microbial Technologies

Cyxone AB

OncBioMune Pharmaceuticals Inc.

Transgene SA

ZIOPHARM Oncology, Inc.

Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) - Drug Profiles

ALKS-4230 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Anti-PD1 Antibody + TILT-123 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Biologic to Activate IL-2 for Graft Versus Host Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BNZ-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Chimeric Antigen Receptor T Cell + TILT-123 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IB-08C175 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Prostatac - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

T-20K - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TG-4010 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TILT-123 + Tumor Infiltrating Lymphocytes - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target CD80 and IL-2 for Acute Myeloblastic Leukemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target IL-2 and E7 Protein for Cervical Cancer and Oropharyngeal Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) - Dormant Projects

Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) - Discontinued Products

Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) - Featured News & Press Releases

Oct 24, 2016: Immunotherapy Expert Dr. Brian Barnett Joins OncBioMune Scientific Advisory Board

Oct 19, 2016: OncBioMune Receives Notice of Patent Allowance for Novel Cancer Vaccine ProscaVax in Mexico

Sep 26, 2016: OncBioMune CEO Dr. Jonathan Head to Present Abstract on Prostate Cancer Vaccine at Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science Into Survival

Aug 08, 2016: Latest Data From Phase 1 Trial of ProscaVax for Prostate Cancer Reinforces Safety and Benefit of Novel Cancer Vaccine

Jul 20, 2016: Pre-Clinical Research Supports Additional Studies of OncBioMune Technology for Breast Cancer Vaccine

Jul 13, 2016: OncBioMune Submits Protocol to Initiate Phase 2/3 Trial of ProscaVax for Prostate Cancer

Jun 14, 2016: OncBioMune Provides Corporate Update; ASCO Reinforces Market Opportunity for New Prostate Cancer Vaccine as Phase 2 Trial Approaches

Jun 02, 2016: Mexican Regulatory Authorities Supportive of OncBioMunes Phase 2 of ProscaVax for Prostate Cancer

May 25, 2016: Alkermes Announces Initiation of Phase 1 Clinical Study of Immuno-Oncology Drug Candidate ALKS 4230

May 18, 2016: Doctors Voice Optimism About Phase 2 Trial of ProscaVax in Mexico for Prostate Cancer

May 11, 2016: OncBioMune Provides Update on Phase 2 Clinical Trials of ProscaVax for Prostate Cancer

May 04, 2016: OncBioMune Submits Protocol to Principal Investigators for Two Phase 2 Clinical Trials of ProscaVax for Prostate Cancer

Apr 28, 2016: OncBioMune Receives Notice of Patent Allowance for Cancer Vaccine ProscaVax in China

Apr 12, 2016: OncBioMune Receives Notice of Patent Allowance for Cancer Vaccine ProscaVax in Hong Kong

Mar 29, 2016: Multiple sclerosis: plant peptide could prevent onset of the disease

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for, H2 2016

Number of Products under Development by Therapy Area, H2 2016

Number of Products under Development by Indication, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Number of Products under Development by Companies, H2 2016

Products under Development by Companies, H2 2016

Number of Products under Investigation by Universities/Institutes, H2 2016

Products under Investigation by Universities/Institutes, H2 2016

Assessment by Monotherapy/Combination Products, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Pipeline by Alkermes Plc, H2 2016

Pipeline by Biomar Microbial Technologies, H2 2016

Pipeline by Cyxone AB, H2 2016

Pipeline by OncBioMune Pharmaceuticals Inc., H2 2016

Pipeline by Transgene SA, H2 2016

Pipeline by ZIOPHARM Oncology, Inc., H2 2016

Dormant Projects, H2 2016

Dormant Projects (Contd..1), H2 2016

Dormant Projects (Contd..2), H2 2016

Discontinued Products, H2 2016

List of Figures

Number of Products under Development for, H2 2016

Number of Products under Development by Therapy Area, H2 2016

Number of Products under Development by Top 10 Indication, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy/Combination Products, H2 2016

Number of Products by Mechanism of Actions, H2 2016

Number of Products by Stage and Mechanism of Actions, H2 2016

Number of Products by Routes of Administration, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Molecule Types, H2 2016

Number of Products by Stage and Molecule Type, H2
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Alkermes Plc
  • Biomar Microbial Technologies
  • Cyxone AB
  • OncBioMune Pharmaceuticals Inc.
  • Transgene SA
  • ZIOPHARM Oncology, Inc.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll